Delivery Order SPE2DB20D2104-SPE2DB22FS21Y
- Not listed
- This federal contract award, valued at $3,722.04, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,560,799,951 units of Naloxone HCL 4 mg Nasal Spray, a critical medication used to treat opioid overdoses. This is a firm-fixed-price delivery order contract with a completion date of May 3, 2023. AmerisourceBergen, a subsidiary of the parent company Cencora,...
- This federal contract award, valued at $1,838.72, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,567,999,320 units of Naloxone HCl 4 mg Nasal Spray, a critical medication used to treat opioid overdoses. This delivery order contract has a firm fixed-price pricing type and an ultimate completion date of April 23, 2025. Amerisourcebergen Drug Corp also...
- This federal contract award, valued at $12,960.05, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of 4,562,251,316 units of 4 mg Naloxone HCL nasal spray, a critical medication used to reverse opioid overdoses. This is a firm fixed-price delivery order contract with a completion date of September 21, 2023. The contract was awarded on an open competition basis,...
- This federal contract award, valued at $4,649.90, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,567,421,527 units of Naloxone Hydrochloride 4 mg Nasal Spray, a critical medication used to reverse opioid overdoses. This is a firm-fixed price delivery order contract with a completion date of March 3, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award, valued at $4,410.87, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,559,419,724 units of Naloxone HCl 4 mg Nasal Spray 2s, a critical medication used for the treatment of opioid overdose. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support...
- This federal contract award, valued at $6,799.63, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of 4,562,493,398 units of Naloxone HCL 4 mg Nasal Spray, a critical medication used for the treatment of opioid overdose. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. (doing business...
- This federal contract award, valued at $2,397.78, was granted by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,563,143,368 units of Naloxone HCL 4 mg Nasal Spray, with a completion date of December 20, 2023. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00. This...
- This federal contract award, valued at $1,685.15, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4 mg Naloxone HCl nasal spray, a critical medication used to treat opioid overdoses. The contract has a period of performance through February 27, 2025 and utilizes a firm fixed-price pricing structure. The award is not associated with a set-aside program and represents an open competition....
- The federal contract award is for the delivery of 4,561,847,733 units of 4 mg naloxone hydrochloride nasal spray, a critical medication used to treat opioid overdose. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA), a component of the Department of Defense. The contract, valued at $10,829.60, is a firm fixed-price delivery order with an ultimate completion date of August 18, 2023. Amerisourcebergen Drug Corp is...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,524.80 firm fixed price delivery order is for the supply of 4 mg Naloxone HCl nasal spray, a critical medication used to treat opioid overdose. The contract has an ultimate completion date of January 29, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB22FS21YDelivery Order
This federal contract award, valued at $9,121.93, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,556,709,275 units of Naloxone HCl 4 mg Nasal Spray, a critical medication used to treat opioid overdoses. This contract is not designated as a set-aside and was awarded through open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which operates under the Amerisourcebergen brand name. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Additionally, Cencora, Inc. maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.1k | 3/28/22 |